Letter: vedolizumab drug concentrations in neonates following intrauterine exposure

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1328-1330. doi: 10.1111/apt.15027.

Authors

Emma Flanagan¹, Peter R Gibson², Jakob Begun³, Simon Ghaly⁴, Mayur Garg⁵, Jane M Andrews⁶, Ourania Rosella⁷, Gennaro Rosella⁷, Sally J Bell¹

Affiliations

¹ St Vincent's Hospital, Melbourne, Victoria, Australia.
² Alfred Hospital, Melbourne, Victoria, Australia.
³ Mater Hospital, Brisbane, Queensland, Australia.
⁴ St Vincent's Hospital, Sydney, New South Wales, Australia.
⁵ Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia.
⁶ Royal Adelaide Hospital, Adelaide, South Australia, Australia.
⁷ Monash University Central Clinical School, Melbourne, Victoria, Australia.

PMID: 30488628
DOI: 10.1111/apt.15027

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Humans
Infant, Newborn
Inflammatory Bowel Diseases*
Pregnancy

Substances

Antibodies, Monoclonal, Humanized
vedolizumab